Interleukin-15 and [Alpha](1,3)galactosyl-Expressing Vaccine Combination Therapy for Melanoma

doi 10.31274/rtd-180813-16639
Full Text
Abstract

Available in full text

Date

Unknown

Authors
Publisher

Iowa State University

Related search

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Combination Therapy Targeting the Elevated Interleukin-6 Level Reduces Invasive Migration of BRAF Inhibitor-Resistant Melanoma Cells

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Combination Immunotherapy for Melanoma

JAMA Oncology
Cancer ResearchOncology
2015English

High Antitumor Activity of RLI, an Interleukin-15 (IL-15)-IL-15 Receptor Fusion Protein, in Metastatic Melanoma and Colorectal Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Combination Therapy With F5/35 Fiber Chimeric Conditionally Replicative Adenoviruses Expressing IL-24 Enhances the Antitumor Effect of Temozolomide Against Melanoma

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2018English

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Frontiers in Immunology
AllergyImmunology
2019English

Role of Interleukin-6 and Interleukin-15 in Exercise

MOJ Immunology
2018English

Interleukin and Interleukin Receptor Gene Polymorphisms and Susceptibility to Melanoma

Melanoma Research
DermatologyCancer ResearchOncology
2008English

Melanoma Therapy With Rhenium-Cyclized Alpha Melanocyte Stimulating Hormone Peptide Analogs

2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy